NEW YORK, Dec. 6 (GenomeWeb News) - BioTrove has expanded its lead discovery collaboration with Schering-Plough Research Institute, the research arm of Schering-Plough, the company said today.
Under the terms of the collaboration, BioTrove will use its RapidFire lead-discovery service for assay development and high-throughput screening on an undisclosed number of targets identified by Schering-Plough.
RapidFire is a mass spectrometry-based technology that enables the high-throughput screening of biochemical assays, BioTrove said. The use of mass spectrometry allows for label-free screening of challenging and intractable drug targets using native substrates, the company said.
Financial terms were not disclosed.